Skip to main content
Log in

Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Sickle cell disease (SCD) is a hemoglobinopathy characterized by hemolysis, oxidative stress, and vaso-occlusive crises. Thromboembolism also remains a serious complication and probably underestimated in the SCD. Our objective was to seek the existence of hemostasis abnormalities that predispose to thrombosis such as elevation of FVIII and Physiological inhibitors of coagulation deficiency. We studied 81 patients with SCD, including 32 homozygous S/S, 20 double heterozygous S/β thalassemia and 29 heterozygous S/A. Controls AA were in number 60. For each patient and control we assayed the physiological coagulation inhibitors (Protein C, Protein S and Antithrombin) and the clotting FVIII. We found a significant increase in FVIII in all phenotypes of SCD compared to controls. Also, a significant decrease in levels of protein C and S was observed in patients with sickle cell homozygous or double heterozygous S β Thalassemia compared to controls. As against, for antithrombin no difference was observed between patients and controls. These hemostasis abnormalities therefore reflect the existence of a pro thrombotic state in sickle cell disease that can explain the increase of incidence of thrombosis in this pathology. Factor VIII clotting consistently high in SCD may well be a prime therapeutic target in the treatment of thrombotic manifestations of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Wajcman H, Lantz B, Girot R (1992) Les maladies du globule rouge. Les éditions INSERM Médecine-Sciences Flammarion, Paris

    Google Scholar 

  2. Embury SH, Hebbel RP, Mohandas N, Steinberg MH (1994) Sickle cell disease. In: Basic principles and clinical practice. Raven Press, New York, pp 311–326

  3. Francis RB, Johnson CS (1991) Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 77:1405–1414

    PubMed  Google Scholar 

  4. Naik RB (2013) Venous thromboembolism in adults with sickle cell disease, a serious and under recognized complication. An/Med 126:443–449

    PubMed  Google Scholar 

  5. Abad MT (2009) Les syndromes drépanocytaires en algérie: épidémiologie nationale 1996–2005. Revue algérienne d’hématologie 1:29–31

    Google Scholar 

  6. Koster T, Blann AD, Briet E, Vandenbrouke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vem thrombosis. Lancet 345:152–155

    Article  CAS  PubMed  Google Scholar 

  7. Rosendaal FR (1997) Risk factors for venous thrombosis prevalence, risk and interaction. Semin Hematol 34:171–187

    CAS  PubMed  Google Scholar 

  8. Lane DA, Mannucci PM, Bauer KA et al (1996) Inherited thrombophila Part l. Thromb Haemost 76:651–662

    CAS  PubMed  Google Scholar 

  9. Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353:1167–1173

    Article  CAS  PubMed  Google Scholar 

  10. Pakbaz Z, Wun T (2014) Role of the hemostatic system on SCD pathophysiology and potential therapeutics. Hematol Oncol Clin North Am 28(2):355–374

    Article  PubMed  PubMed Central  Google Scholar 

  11. Solovey A, Kollander R, Shet A et al (2004) Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 104(3):840–846

    Article  CAS  PubMed  Google Scholar 

  12. Setty BN, Kulkani S, Stuart MJ (2002) Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 99:1564–1571

    Article  CAS  PubMed  Google Scholar 

  13. Shet AS, Aras O, Gupta K et al (2003) Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102:2678–2683

    Article  CAS  PubMed  Google Scholar 

  14. de Montalembert M (2002) Traitement de la drépanocytose par l’hydroxyurée. Hematologie 8:28–34

    Google Scholar 

  15. Ware RE, Aygun B (2009) Advances in the use of hydroxyurea. Hematol Am Soc Hematol 1:62–69

    Google Scholar 

  16. Koc A, Gumruk F, Gurgey A (2003) The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. Pediatr Hematol Oncol 20(6):429–434

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mohamed Chekkal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chekkal, M., Rahal, M.C.A., Moulasserdoun, K. et al. Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease. Indian J Hematol Blood Transfus 33, 235–238 (2017). https://doi.org/10.1007/s12288-016-0701-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-016-0701-z

Keywords

Navigation